Background: CMBs have long been regarded to be an early imaging indication of haemorrhage -recumbent vasculopathy -and consequently a predictor of symptomatic stroke, especially intracerebral haemorrhage, and dementia in old life. Aim of the study:The primary goal of this study was to investigate the prevalence and risk factors for cerebral microbleeds (CMB) in acute ischemic stroke using T2* weighted imaging. Patients and Methods: The 6-month Prospective Cohort Study was repeated with the same This study includes 150 cases from the inpatient and outpatient clinics of Al-Azhar University Hospitals' neurology departments. MRI brain T2* was utilised to determine the presence or absence of cerebral microbleeds after an acute ischemic stroke diagnosis was made based on clinical, radiographic, and laboratory data. Results: Microbleeds in the brain were discovered to be prevalent in 21.3 percent of people. In terms of tobacco smoke, raised blood pressure, D.M, atrial fibrillation, ischemic heart disease, and hyperlipidemia, there were statistically non-significant differences between those with negative and positive CMB. Patients with a positive CMB had a statistically significant increase in antiplatelet medication use compared to those with a negative CMB, according to the current data. Conclusion: Cerebral microbleeds were identified in 21.3 percent of patients over the age of 65 who had an ischemic stroke. One of the most significant risk factors connected to the development of CMBs has been identified as antiplatelet medications.